Clinical Study Confirms Arla’s Lacprodan IF-3070 Supports Healthy Infant Growth

KUALA LUMPUR, March 25 (Bernama) -- Infant formula containing Arla Foods Ingredients’ Lacprodan IF-3070 was well tolerated and supports healthy growth and development in newborns, according to a clinical study published in Nutrients.

According to Arla Foods Ingredients in a statement, the findings provide essential scientific evidence for formula development in early life nutrition.

Arla Foods Ingredients Chief Scientist, Early Life Nutrition, Lotte Neergaard Jacobsen said healthy growth is a key factor in infant formula purchases.

Jacobsen added that the company is delighted that the first clinical study on Lacprodan IF-3070 has confirmed that it supports healthy growth.

Lacprodan IF-3070 is a partially hydrolysed whey protein ingredient specially designed to support gastrointestinal comfort in healthy infants.

The study, conducted across six Chinese hospitals with 251 newborns under 14 days old, compared standard formula, formula with approximately 40 per cent Lacprodan IF-3070, and breastfed infants as a reference.

After six months, growth trajectories for infants receiving the Lacprodan IF-3070 formula were found to be closer to the breastfed reference group, with mean daily weight gain differences of only 0.4 grammes (g) per day, compared to a 1.1 g per day difference for the standard formula group.

In terms of tolerance, there were no significant differences in adverse event incidence (gastrointestinal disorders, respiratory diseases or general disorders) between the Lacprodan IF-3070 group and the breastfed group, while the standard formula group had higher gastrointestinal disorder incidence.

Lacprodan IF-3070 is part of Arla Foods Ingredients’ hydrolysate portfolio and can be used in China and the United States, following the Food and Drug Administration (FDA)'s 2024 approval of whey protein hydrolysates in infant formula.

-- BERNAMA